Legend Biotech Corp 2024 SR
The report highlights Legend Biotech's commitment to integrating ESG principles into its global cell therapy operations. In 2024, the company achieved a significant milestone with the approval of CARVYKTI for second-line treatment of multiple myeloma in the U.S. and Europe. Legend Biotech invested over $266 million in research and development and expanded its global footprint with a new R&D facility in Philadelphia and commercial production in Belgium. The company also strengthened its ESG governance by forming a cross-functional ESG Committee and hiring an ESG Controller. Environmental efforts focused on calculating Scope 1 and 2 emissions and pursuing LEED Gold certification for new facilities.
Company: Legend Biotech Corp
Sector: Health Care
Country: United States
Year: 2024
Type: SR
Pages: 46
Legend Biotech Corp
ESG Report
The report highlights Legend Biotech's commitment to integrating ESG principles into its global cell therapy operations. In 2024, the company achieved a significant milestone with the approval of CARVYKTI for second-line treatment of multiple myeloma in the U.S. and Europe. Legend Biotech invested over $266 million in research and development and expanded its global footprint with a new R&D facility in Philadelphia and commercial production in Belgium. The company also strengthened its ESG governance by forming a cross-functional ESG Committee and hiring an ESG Controller. Environmental efforts focused on calculating Scope 1 and 2 emissions and pursuing LEED Gold certification for new facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Apr 10, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Workplace Fatalities
Employees